Tranylcypromine dependence and withdrawal

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 6, 2009, Pages 580-581

  Shaikh, Wasim ^a   Fuls, Karin ^a  

^a Metro South Health   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; OXAZEPAM; TRANYLCYPROMINE;

AGED; AGITATION; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG DEPENDENCE; DYSARTHRIA; FAHR DISEASE; HUMAN; LABORATORY DIAGNOSIS; LETTER; MALE; MANIA; MENTAL INSTABILITY; NUTRITIONAL ASSESSMENT; PATIENT MONITORING; PSYCHOLOGIC TEST; PSYCHOSIS; THROMBOCYTOPENIA; WITHDRAWAL SYNDROME;

AGED; HUMANS; MALE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TRANYLCYPROMINE;

EID: 68049105293     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670902873748     Document Type: Letter

References (5)

1. Le Gassicke J. Tranylcypromine. Lancet 1963; i: 269-270.
2. Le Gassicke J, Ashcroft GW, Eccleston D, Evans JI, Oswald I, Ritson EB. The clinical state, sleep and amine metabolism of a tranylcypromine (Parnate) addict. Br J Psychiatry 1965; 111:357-364.
3. Shopsin B, Kline NS. Monoamine oxidase inhibitors: Potential for drugabuse. Biol Psychiatry 1976; 11:451-456.
4. Halle MT, Dilsaver SC. Tranylcypromine withdrawal phenomena. J Psychiatr Neurosci 1993; 18:49-50.
5. Shakibai SV, Johnson JP, Bourgeois JA. Paranoid delusions and cognitive impairment suggesting Fahr's disease. Psychosomatics 2005; 46:569-572